The trial reportedly showcased significant weight reduction in those treated with VK2735, a dual GLP-1/GIP receptor agonist.
Viking Therapeutics’ GLP-1/GIP Receptor Agonist Shows Positive Results in Obesity Clinical Trial
The trial reportedly showcased significant weight reduction in those treated with VK2735, a dual GLP-1/GIP receptor agonist.